IBA Notice of Full Year 2024 Results and Conference Call

FY24 results meeting to take place as a hybrid event on Thursday, 20 March 2025 at 2:30pm CET

Louvain-la-Neuve, Belgium, 27 February 2025 - IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology, announces today that it will publish its consolidated results for the full year 2024 on Thursday, 20 March 2025 at 7am CET.

Conference Call Information

IBA’s management team will host a hybrid event, including a conference call and webcast conducted in English, to present the full year results, followed by a Q&A session.

The conference call will be held on Thursday, 20 March 2025 at 2:30pm CET / 1:30pm GMT / 9:30am ET / 6:30am PT as a Teams webinar and can be accessed online on .

If you would like to join by phone only, please dial (Phone conference ID 393 230 94#)

Belgium:                    

UK:                             0

NL:                             

LU:                              2

US:                            

FR:                              51

The presentation will be available on website and on shortly before the call.

To ensure a timely connection, it is recommended that users register at least 10 minutes prior to the scheduled webcast.

For participants who do not have the Teams application installed, please follow the process described in to access the conference.

ENDS

About IBA

IBA (Ion Beam Applications S.A.) is the world leader in particle accelerator technology. The company is the leading supplier of equipment and services in the fields of proton therapy, considered to be the most advanced form of radiation therapy available today, as well as industrial sterilization, radiopharmaceuticals and dosimetry. The company, based in Louvain-la-Neuve, Belgium, employs approximately 2,000 people worldwide. IBA is a certified B Corporation (B Corp) meeting the highest standards of verified social and environmental performance.

IBA is listed on the pan-European stock exchange EURONEXT (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB).

More information can be found at:

CONTACTS

Olivier Lechien

Corporate Communication Director

ICR Healthcare

Amber Fennell, Angela Gray, Chris Welsh

+44 (0) 20 3709 5700

Attachment